Anti-Mouse IL-1α (Clone 40508)

Purified Recombinant Mouse IL-1α (>98%)

This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.

The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Neutralization: This antibody is useful for neutralization of Mouse IL-1α bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Mouse IL-1α (at 50 ng/ml) is 0.2 - 0.6 µg/ml.

Clone 40508 recognizes an epitope on mouse IL-1α.

IL-1R1 is an 80 kD transmembrane glycoprotein and a member of the Ig superfamily. IL-1 binds both IL-1R1 and IL-1R2. The ligands IL-1α and IL-1β only commence when binding IL-1R1 because IL-1R2 acts as a decoy receptor and competitively antagonizes the binding of IL-1α and IL-1β, thereby reducing their biological effects. Binding of the ligands to IL-1R1 is enhanced by an accessory protein, IL-1R-AcP. IL-1α can exist as either a 31 kD precursor or an 18 kD mature form. IL-1α is a proinflammatory cell-associated cytokine and IL-1β is a 17.5 kD proinflammatory secreted cytokine. Both IL-1α and IL-1β bind to the same receptor and have similar properties that include stimulation of thymocyte proliferation via IL-2 release, B-cell maturation and proliferation, mitogenic FGF-like activity and the ability to stimulate the release of prostaglandin and collagenase from synovial cells. Furthermore, IL-1β mediates a variety of immune and inflammatory responses. IL-1β is a major cause of severe inflammation in the mouse model of Crohn’s Disease, which makes IL-1β an important target for this disease.

1.) Sasaki et. el; The Journal of Immunology July 17, 2013, 1202194 Journal Link